2025-08-29 - Analysis Report
Okay, here's a report summarizing the provided data for Johnson & Johnson (JNJ), including key metrics, analysis, and a final consolidated view.

## Johnson & Johnson (JNJ) Analysis

**Company Overview:** Johnson & Johnson is a global healthcare company that develops and manufactures pharmaceuticals, medical devices, and consumer packaged goods.

**1. Performance vs. S&P 500 (VOO)**

*   **JNJ Cumulative Return:** 29.62%
*   **VOO (S&P 500) Cumulative Return:** 102.60%
*   **Relative Divergence:** -142.8
*   **Relative Divergence (Percentile):** 9.0
    *This indicates JNJ has significantly underperformed the S&P 500 over the period. The relative divergence percentile suggests JNJ's underperformance is near the lower end of its historical range compared to the S&P 500.*

**Alpha, Beta Analysis Table**

| Year       | CAGR    | MDD     | Alpha   | Beta  | Cap(B) |
|------------|---------|---------|---------|-------|--------|
| 2015-2017  | 28.0%   | 56.1%   | -1.0%   | -0.0  | 336.5  |
| 2016-2018  | 8.0%    | 56.6%   | -10.0%  | 0.0   | 310.8  |
| 2017-2019  | 18.0%   | 56.6%   | -12.0%  | 0.7   | 351.3  |
| 2018-2020  | 12.0%   | 59.2%   | -8.0%   | 0.3   | 379.0  |
| 2019-2021  | 32.0%   | 59.6%   | -16.0%  | 0.2   | 412.0  |
| 2020-2022  | 7.0%    | 61.4%   | 5.0%    | 0.2   | 425.4  |
| 2021-2023  | -15.0%  | 61.4%   | -33.0%  | 0.4   | 377.5  |
| 2022-2024  | -35.0%  | 61.4%   | -61.0%  | 0.3   | 348.3  |
| 2023-2025  | 2.0%    | 70.1%   | -52.0%  | 0.2   | 422.5  |

*   **CAGR:** Varies significantly, with negative growth in recent periods (2021-2025).
*   **MDD:**  Maximum Drawdown is consistently high, indicating substantial potential losses.
*   **Alpha:**  Largely negative, showing underperformance relative to the market, especially in recent years.
*   **Beta:** Consistently below 1, meaning the stock is less volatile than the market.
*   **Cap(B):** Market capitalization fluctuates, reflecting market conditions.

**Analysis:**  The historical performance data shows a concerning trend of underperformance (negative alpha) and high maximum drawdowns. While the beta suggests lower volatility, the negative alpha indicates the stock is not generating excess returns compared to its benchmark.

**2. Recent Stock Price Movement**

*   **Current Price:** 175.45
*   **Previous Close:** 176.79
*   **Change:** -0.76
*   **5-day Moving Average:** 177.29
*   **20-day Moving Average:** 174.76
*   **60-day Moving Average:** 163.62

**Analysis:**  The current price is slightly down from the previous close. The 5-day moving average is above the current price, suggesting a short-term downward trend.  The 20-day moving average is slightly below the current price, and the 60-day moving average is significantly lower, indicating a longer-term upward trend that might be losing momentum.

**3. Market Risk Indicator & Other Indicators**

*   **Market Risk Indicator (MRI):** 0.33 (Low Risk)
*   **RSI:** 57.99
*   **PPO:** -0.33
*   **Hybrid Signal:** Cash_59%_Sell 59.2% of holdings
*   **Recent (20-day) Relative Divergence Change:** 1.5 (Positive - short term increase)
*   **Expected Return (%):** -710.6

**Analysis:**

*   **MRI:** Indicates a low-risk market environment, but the hybrid signal suggests caution.
*   **RSI:** Is near the 60 level, suggesting that the stock has upward price momentum.
*   **PPO:** Negative, implying the short-term moving average is below the long-term moving average, potentially signaling a downtrend.
*   **Hybrid Signal:** The strong "Sell" signal with a significant cash allocation suggests a bearish outlook based on the model's indicators.
*   **Recent Divergence Change:**  The positive change in relative divergence suggests a short-term improvement in JNJ's performance relative to the S&P 500.
*   **Expected Return:** The significantly negative expected return suggests that, from the current point, long-term investment in the stock is projected to underperform the S&P 500 significantly.

**4. Recent News & Significant Events**

*   **[2025-08-25]:** Major business developments, regulatory changes, or market events.
*   **[2025-08-29]:** Analyst discussions on performance and outlook.
*   **[2025-08-28]:** Notable stock volatility.
*   **[2025-08-27]:** Experts highlighting risks and opportunities.

**Analysis:**  The recent news indicates that JNJ is experiencing significant market activity and analyst scrutiny, likely due to recent developments. The volatility noted suggests uncertainty surrounding the stock.

**5. Recent Earnings Analysis**

| 날짜       | EPS  | 매출          |
|------------|------|---------------|
| 2025-07-24 | 2.3  | 23.74 B$      |
| 2025-04-23 | 4.57 | 21.89 B$      |
| 2024-10-23 | 1.12 | 22.47 B$      |
| 2024-07-25 | 1.95 | 22.45 B$      |
| 2025-07-24 | 1.95 | 22.45 B$      |

**Analysis:** The Q3 2025 sales and profit are better than expected, but Q3 2025 EPS is lower than Q2 2025.

**6. Financial Information**

**Revenue and Profitability**

| Quarter    | Revenue    | Profit Margin |
|------------|------------|---------------|
| 2025-06-30 | $23.74B    | 67.87%        |
| 2025-03-31 | $21.89B    | 66.40%        |
| 2024-12-31 | $22.52B    | 68.35%        |
| 2024-09-30 | $22.47B    | 69.01%        |
| 2024-06-30 | $22.45B    | 69.40%        |

**Capital and Profitability**

| Quarter    | Equity     | ROE     |
|------------|------------|---------|
| 2025-06-30 | $78.47B    | 7.06%   |
| 2025-03-31 | $78.11B    | 14.08%  |
| 2024-12-31 | $71.49B    | 4.80%   |
| 2024-09-30 | $70.16B    | 3.84%   |
| 2024-06-30 | $71.54B    | 6.55%   |

**Analysis:**

*   **Revenue:**  Shows some fluctuation, with the most recent quarter (2025-06-30) showing a slight increase.
*   **Profit Margin:**  Consistently high, indicating strong profitability.
*   **Equity:** Gradually increasing.
*   **ROE:**  Fluctuates but remains relatively stable, indicating a good return on equity, but there is a notable drop-off in recent quarters.

**7. Overall Summary**

Johnson & Johnson (JNJ) is currently facing a complex situation. While the company exhibits strong financial health with consistent revenue and profit margins, it has significantly underperformed the S&P 500. The technical indicators present a mixed picture, with short-term downward price momentum and a strong "Sell" signal from the hybrid model. Recent news suggests the company is experiencing significant market activity and analyst attention. The negative expected return for the long term suggests there are better investment options in the market. The company's high market capitalization and relatively low beta may appeal to some investors as a stable investment during uncertain economic times.

**Disclaimer:** This analysis is based on the provided data and should not be considered financial advice. Always consult with a qualified financial advisor before making investment decisions.
